Yiping Li is a distinguished leader in the biopharmaceutical industry, currently serving as the Founder and Chief Scientific Officer at Oak Biosciences Inc. With over 12 years of extensive experience in antibody engineering, molecular biology, and cell biology, Yiping has successfully bridged the gap between...
Yiping Li is a distinguished leader in the biopharmaceutical industry, currently serving as the Founder and Chief Scientific Officer at Oak Biosciences Inc. With over 12 years of extensive experience in antibody engineering, molecular biology, and cell biology, Yiping has successfully bridged the gap between academic research and industrial application. His role at Oak Biosciences Inc. involves spearheading innovative projects that leverage next-generation phage display bio-panning techniques for the development of high-affinity antibodies and peptides. Under his guidance, the company has made significant strides in chimeric antibody generation, humanization, and affinity maturation, positioning itself at the forefront of therapeutic antibody development.
Yiping's expertise extends to advanced genome engineering and editing, where he has led initiatives in chromosome engineering and the creation of robust cell lines tailored for high-throughput screening. His proficiency in directed evolution and the development of DNA and RNA aptamers has enabled Oak Biosciences to pioneer novel assay platforms, including immuno-PCR and real-time qPCR methodologies. With a strong publication record, Yiping is not only a thought leader in the field but also a mentor who cultivates a highly focused and productive research team. His commitment to innovation and excellence in antibody/protein engineering continues to drive the company’s mission to deliver cutting-edge biotherapeutics that address unmet medical needs. As Oak Biosciences Inc. expands its portfolio, Yiping remains dedicated to advancing the science of protein interactions and enhancing therapeutic efficacy through strategic research initiatives.
